AUTOLOGOUS CD34+ CELL TRANSPLANT FOR ISCHEMIC TISSUE REPAIR

Abstract number: SYM-S-021

Losordo¹ D.W.

¹Cardiology, Northwestern University, Chicago, United States

How-to-cite Losordo DW. AUTOLOGOUS CD34+ CELL TRANSPLANT FOR ISCHEMIC TISSUE REPAIR. J Thromb Haemost 2007; 5 Supplement 2: SYM-S-021

Abstract

As the population ages and the acute mortality from cardiovascular disease decreases, a large population of patients is emerging who have symptomatic chronic ischemic vascular disease, many of whom remain severely symptomatic despite exhausting conventional medical therapy and mechanical revascularization. In addition, mounting evidence suggests that microvascular insufficiency plays a significant role in the pathophysiology of ischemia. At the present time, there are no therapies that directly address the needs of this patient population.

Pre-clinical and early clinical data indicate that a variety of growth factors and stem/progenitor cells may be employed therapeutically for repair of ischemic tissue. Initial pilot studies, employing naked plasmid DNA encoding VEGF provided evidence of safety and feasibility of site specific gene therapy for limb and myocardial ischemia. These studies are now being extended in large, randomized controlled trials.

Moreover the initial studies of angiogenic gene therapy also revealed that mobilization of endothelial progenitor cells occurred following gene transfer. These observations led to preclinical studies that documented the therapeutic potency of endothelial progenitor cells, both as cultured cells and freshly isolated as CD34+ cells. A pilot clinical trial has now been completed providing data of feasibility, safety and bioactivity of intramyocardial transplantation of autologous CD34+ cells for treatment of intractable angina.

Accordingly, the goal of ischemic tissue repair appears feasible and is being approached in human clinical trials. The evolution of this strategy will require an ongoing dialogue between clinicians, scientists, regulators and industry to take full advantage of advances in our understanding of the biology of these processes and their appropriate application to patients.

To cite this abstract use the following format:

Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number

Session Details

Date:	01/08/2007
Time:	00:00-00:00
Session name:	XXIst ISTH Congress
Subject:
Location:	Oxford, UK
Presentation type:
Back to top